Electron Transport Chain: Complex I and II
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Mitochondrial Membranes
Mitochondria
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Jan 5, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
Mélissa Léveillé1,2, Jennifer L Estall3,4,5
1Institut de Recherches Cliniques de Montréal (IRCM), Montreal, Quebec, QC H2W 1R7, Canada. Melissa.Leveille@ircm.qc.ca.
Mitochondrial dysfunction plays a key role in chronic liver diseases like non-alcoholic steatohepatitis (NASH) and liver cancer (HCC). Targeting mitochondria may offer new treatments for these conditions.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: